1. Home
  2. REGN vs LRCX Comparison

REGN vs LRCX Comparison

Compare REGN & LRCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • LRCX
  • Stock Information
  • Founded
  • REGN 1988
  • LRCX 1980
  • Country
  • REGN United States
  • LRCX United States
  • Employees
  • REGN N/A
  • LRCX N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • LRCX Industrial Machinery/Components
  • Sector
  • REGN Health Care
  • LRCX Technology
  • Exchange
  • REGN Nasdaq
  • LRCX Nasdaq
  • Market Cap
  • REGN 63.4B
  • LRCX 81.4B
  • IPO Year
  • REGN 1991
  • LRCX N/A
  • Fundamental
  • Price
  • REGN $547.67
  • LRCX $74.90
  • Analyst Decision
  • REGN Buy
  • LRCX Buy
  • Analyst Count
  • REGN 23
  • LRCX 24
  • Target Price
  • REGN $907.39
  • LRCX $92.75
  • AVG Volume (30 Days)
  • REGN 1.2M
  • LRCX 12.4M
  • Earning Date
  • REGN 04-29-2025
  • LRCX 04-23-2025
  • Dividend Yield
  • REGN 0.32%
  • LRCX 1.23%
  • EPS Growth
  • REGN 16.49
  • LRCX 32.12
  • EPS
  • REGN 39.43
  • LRCX 3.59
  • Revenue
  • REGN $14,085,700,000.00
  • LRCX $17,135,705,000.00
  • Revenue This Year
  • REGN $2.38
  • LRCX $21.55
  • Revenue Next Year
  • REGN $7.65
  • LRCX $2.25
  • P/E Ratio
  • REGN $14.23
  • LRCX $20.87
  • Revenue Growth
  • REGN 7.52
  • LRCX 20.32
  • 52 Week Low
  • REGN $520.50
  • LRCX $56.32
  • 52 Week High
  • REGN $1,211.20
  • LRCX $113.00
  • Technical
  • Relative Strength Index (RSI)
  • REGN 38.69
  • LRCX 58.29
  • Support Level
  • REGN $542.44
  • LRCX $72.59
  • Resistance Level
  • REGN $615.61
  • LRCX $75.49
  • Average True Range (ATR)
  • REGN 22.06
  • LRCX 1.95
  • MACD
  • REGN -0.13
  • LRCX 1.05
  • Stochastic Oscillator
  • REGN 28.57
  • LRCX 90.05

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About LRCX Lam Research Corporation

Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.

Share on Social Networks: